描述人类胎盘衍生外体 (pExo) 作为潜在的骨关节炎疾病修饰治疗
Chenfei Huang1, Yuechao Zhao2, Shengchen Lin1
1Celularity Inc., 170 Park Avenue, Florham Park, NJ, 07932, USA.
Arthritis research & therapy
|November 29, 2023
概括
人类胎盘衍生外体 (pExo) 在骨关节炎 (OA) 治疗方面表现有前途. 这些外体减轻OA症状,并可能改变疾病,提供潜在的新疗法.
科学领域:
- 生物医学研究的研究.
- 再生医学是一种再生医学.
- 骨关节炎的治疗方法
背景情况:
- 骨关节炎 (OA) 是一种退行性关节疾病,有效治疗方法有限.
- 外体,特别是来自人胎盘 (pExo) 的外体,正在研究它们的治疗潜力.
研究的目的:
- 评估人类胎盘衍生外体 (pExo) 作为骨关节炎 (OA) 的潜在治疗剂.
- 描述pExo并评估其对冠状细胞及其在体内OA模型中的影响.
主要方法:
- pExo从人类胎盘中分离出来,并以大小,标记物和蛋白质含量进行了表征.
- 在体外研究中评估了pExo对人体冠状细胞的影响,包括增殖和炎症基因表达.
- 活体疗效在老鼠OA模型 (MCLT + MMT) 中使用关节内注射,重量轴承分析和终端终点评估进行了测试.
主要成果:
- 具有特征的pExo表现出典型的外体特性,并含有生物活性蛋白质.
- 在体外,pExo促进了冠状细胞的迁移和增殖,并抑制了与OA相关的炎症和代谢基因表达.
- 在体内,pExo治疗减少了疼痛,恢复了软骨,并降低了剂量依赖的促炎,催化和亡标志物.
结论:
- 人类胎盘衍生外体 (pExo) 显示出骨关节炎的显著治疗潜力.
- pExo既具有控制症状和改变疾病的特性.
- pExo代表了作为抗OA治疗剂进一步开发的有吸引力的候选人.
相关概念视频
Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K


